Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

<< Previous

Bullboard Posts

Next >>

Comment by Lee430on Nov 27, 2024 11:45am

43 Views

Post# 36333696

RE:RE:RE:RE:New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

Thera, It’s tax loss harvesting season again so this sure would be a good time to maybe consider engaging with the market before we break below $1.0

PWIB123 wrote: Never in my life have I seen a company so bad at public communication.

Trogarzon wrote: If the same applies to our Egrifta shortage we'll be out of our investment money in 10 months and IQ will own the company. They'll probably celebrate with the C-Suite and linkedin the news.